ProCE Banner Activity

Multiple Receptor TKIs in Recurrent GBM in the Absence of Actionable Targets

Slideset Download
In this downloadable slideset, Manmeet S. Ahluwalia, MD, FACP, highlights regorafenib in the REGOMA trial and other multiple receptor kinase inhibitors for patients with GBM.

Released: November 22, 2019

Expiration: November 20, 2020

No longer available for credit.

Share

Faculty

Manmeet S. Ahluwalia

Manmeet S. Ahluwalia, MD, FACP

Professor, Department of Medicine
Clinic Lerner College of Medicine
Case Western Reserve Universtiy
Dean, Diane Miller Family Endowed Chair in Neuro-Oncology
Director, Brain Metastasis Research Program
Associate Director, Head of Operations
Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center
Neurological Institute of Cleveland Clinic
Cleveland, Ohio

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bayer Healthcare Pharma

Faculty Disclosure

Primary Author

Manmeet S. Ahluwalia, MD, FACP

Professor, Department of Medicine
Clinic Lerner College of Medicine
Case Western Reserve Universtiy
Dean, Diane Miller Family Endowed Chair in Neuro-Oncology
Director, Brain Metastasis Research Program
Associate Director, Head of Operations
Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center
Neurological Institute of Cleveland Clinic
Cleveland, Ohio